Cel-Sci Corp. (CVM)
NYSE MKT:CVM
Holding CVM?
Track your performance easily

Cel-Sci (CVM) Stock Price & Analysis

708 Followers

CVM Stock Chart & Stats


Financials

Annual

Ownership Overview

2.50%4.71%0.03%88.93%
0.03% Other Institutional Investors
88.93% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

CVM FAQ

What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.00 and its highest was $3.23 in the past 12 months.
    What is Cel-Sci Corp.’s market cap?
    Currently, no data Available
    When is Cel-Sci Corp.’s upcoming earnings report date?
    Cel-Sci Corp.’s upcoming earnings report date is Dec 18, 2024 which is in 65 days.
      How were Cel-Sci Corp.’s earnings last quarter?
      Cel-Sci Corp. released its earnings results on Aug 15, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.14.
        Is Cel-Sci Corp. overvalued?
        According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Cel-Sci Corp. pay dividends?
          Cel-Sci Corp. does not currently pay dividends.
          What is Cel-Sci Corp.’s EPS estimate?
          Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Cel-Sci Corp. have?
          Cel-Sci Corp. has 63,787,106 shares outstanding.
            What happened to Cel-Sci Corp.’s price movement after its last earnings report?
            Cel-Sci Corp. reported an EPS of -$0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.87%.
              Which hedge fund is a major shareholder of Cel-Sci Corp.?
              Currently, no hedge funds are holding shares in CVM
              ---

              Cel-Sci Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -16.52%
              12-Months-Change

              Fundamentals

              Return on Equity
              -244.53%
              Trailing 12-Months
              Asset Growth
              -25.53%
              Trailing 12-Months

              Company Description

              Cel-Sci Corp.

              CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Cellectar Biosciences
              Advaxis
              TRACON Pharmaceuticals
              ImmunityBio
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis